Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Felmingham, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Felmingham, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 1-7
© 2002 The British Society for Antimicrobial Chemotherapy

Supplement

The need for antimicrobial resistance surveillance

David Felmingham*

GR Micro Ltd, 7–9 William Road, London NW1 3ER, UK

Abstract

Although antimicrobial agents drastically reduced patient morbidity and mortality, bacterial resistance to these agents developed shortly after their introduction. Because the laboratory diagnosis of respiratory tract infection (RTI) is not always possible, and rarely of immediate use, treatment success or failure often depends upon the availability of reliable susceptibility information at the time of therapeutic decision-making. Hence, the need for accurate, up-to-date and timely data is obvious. This information can also be used to help determine the cause of antimicrobial resistance and how it spreads. Desired components of a global RTI surveillance study fall into four categories: programme design, methodology, clinical and dissemination of information. PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is an RTI surveillance study designed to fulfil these requirements. PROTEKT includes all of the features of other successful RTI surveillance studies (e.g. the Alexander Project, SENTRY) and improves on these studies by the addition of other desirable features, such as the determination of resistance mechanisms and the availability of up-to-date local data that can be downloaded to hand-held computers via the worldwide web for use at the bedside.

Footnotes

* Tel: +44-20-7388-7320; Fax: +44-20-7388-7324; E-mail: D.Felmingham{at}grmicro.co.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
M. A. Khan, J. B. Northwood, F. Levy, S. J. C. Verhaegh, D. J. Farrell, A. Van Belkum, and J. P. Hays
bro {beta}-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults
J. Antimicrob. Chemother., November 4, 2009; (2009) dkp401v1.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Asche, C. McAdam-Marx, B. Seal, B. Crookston, and C. D. Mullins
Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance
J. Antimicrob. Chemother., May 1, 2008; 61(5): 1162 - 1168.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.